Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate a Multicenter, Randomized, Open, Positive Parallel Controlled Phase III Clinical Trial of Semaglutide Injection (HD1916) in the Treatment of Obesity

NCT06604624 is registered in ClinicalTrials.gov with CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06604624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06604624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate a Multicenter, Randomized, Open, Positive Parallel Controlled Phase III Clinical Trial of Semaglutide Injection (HD1916) in the Treatment of Obesity
Lead sponsor
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 20, 2024
Completion date
September 24, 2025
Enrollment
462 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

weight management